EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Small molecule multitarget antiangiogenic inhibitor treatments for advanced thymic epithelial tumors: A retrospective study

Wanji Shen iD, Ying Jin iD, Ying Yu, Ning Chen, Yun Fan iD

Thoracic Cancer · 2024

DOI: 10.1111/1759-7714.15167 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Thoracic Cancer, 2024. Verfasst von Wanji Shen und 4 weiteren Autor:innen. Beteiligte Einrichtung: Postgraduate Training Base Alliance of Wenzhou Medical University, Wenzhou, China. Hauptthemen laut MEDLINE: Thymus Neoplasms, Thymoma, Neoplasms, Glandular and Epithelial. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Not applicable..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Thymic epithelial tumors (TETs) are rare malignant tumors with limited treatment options. No established second‐line treatment regimen is available following the preferred first‐line chemotherapy, resulting in unsatisfactory efficacy and poor prognosis for patients with advanced TETs. This study aimed to evaluate the efficacy of small molecule multitarget antiangiogenic inhibitors as well as the prognostic factors for advanced TETs.

Methods

A retrospective study was conducted using data from a real‐world database. Clinical information and survival follow‐up data were collected from 52 patients with advanced TETs who received small molecule multitarget antiangiogenic inhibitors at Zhejiang Cancer Hospital between August 10, 2016 and August 10, 2022. The short‐term efficacy of the treatments, survival time of the patients, and relevant prognostic factors of advanced TETs were analyzed.

Results

Out of the 52 patients included in this study, 16 had thymoma and 36 had thymic carcinoma. The 52 patients had an overall response rate of 21.1% and a disease control rate of 94.2%. In addition, the median progression‐free survival (PFS) was 8.05 months, and the overall survival (OS) was 25.00 months. Apatinib was given to 33 patients, anlotinib to 15 patients, and sunitinib or lenvatinib to four patients. Only seven patients received antiangiogenic inhibitors as their first‐line therapy, 27 patients as their second‐line therapy, and 18 patients as third‐line or subsequent therapy. Meanwhile, 42 patients received monotherapy with an antiangiogenesis inhibitor, while 10 patients received combination therapy. Univariate analysis indicated that the combined treatment was associated with a superior OS ( p = 0.044); multivariate analysis indicated that the combined treatment was an independent prognostic factor for PFS ( p = 0.014) and OS ( p = 0.012).

Conclusion

The findings suggest that small molecule multitarget antiangiogenic inhibitors are efficacious as second or post‐line treatments as a viable alternative treatment option for patients with advanced TETs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Thymus NeoplasmsThymomaNeoplasms, Glandular and EpithelialHumansRetrospective Studies

Stichwörter der Autor:innen

small molecule multitarget antiangiogenic inhibitorsthymic carcinomathymic epithelial tumorthymoma

Autor:innen und Institutionen

  • Postgraduate Training Base Alliance of Wenzhou Medical University, Wenzhou, China.
  • Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, China.
  • Department of Oncology, The Second Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou, China.

ORCID-Profile: Wanji Shen, Ying Jin, Yun Fan

Förderung

  • Not applicable.

Zitieren

APA

Shen, W., Jin, Y., Yu, Y., Chen, N., & Fan, Y. (2024). Small molecule multitarget antiangiogenic inhibitor treatments for advanced thymic epithelial tumors: A retrospective study. Thoracic Cancer. https://doi.org/10.1111/1759-7714.15167

Vancouver

Shen W, Jin Y, Yu Y, Chen N, Fan Y. Small molecule multitarget antiangiogenic inhibitor treatments for advanced thymic epithelial tumors: A retrospective study. Thoracic Cancer. 2024. doi:10.1111/1759-7714.15167

BibTeX
@article{Shen2024,
  author = {Shen, Wanji and Jin, Ying and Yu, Ying and Chen, Ning and Fan, Yun},
  title = {Small molecule multitarget antiangiogenic inhibitor treatments for advanced thymic epithelial tumors: A retrospective study},
  journal = {Thoracic Cancer},
  year = {2024},
  doi = {10.1111/1759-7714.15167}
}
Kostenlos starten →